胶质母细胞瘤遗传驱动因素决定TAM功能及CSF1R抑制反应
研究通过构建PDGFB驱动和RAS驱动的同源胶质母细胞瘤模型,发现CSF1R抑制剂PLX3397显著抑制PDGFB驱动肿瘤生长,但早期清除TAM加速RAS驱动肿瘤生长。单细胞转录组揭示不同亚型TAM功能异质,联合抗血管生成可改善RAS驱动肿瘤对CSF1R抑制的抵抗。
要点
- CSF1R抑制对PDGFB驱动胶质瘤有效,对RAS驱动可能促瘤。
- TAM亚群功能异质,PDGFB肿瘤富集促瘤小胶质细胞。
- RAS驱动间质样胶质瘤可尝试CSF1R抑制联合抗血管生成。
核心结论
- 不同胶质瘤亚型的TAM功能不同,决定CSF1R抑制疗效。
- RAS驱动间质样胶质瘤对CSF1R抑制抵抗,但联合抗血管生成可能有效。
研究设计与样本
- 构建PDGFB驱动和RAS驱动的同源胶质母细胞瘤模型。
- 使用CSF1R抑制剂PLX3397处理,观察肿瘤生长。
- 采用单细胞转录组分析肿瘤微环境细胞组成与功能。
主要发现
- PLX3397显著抑制PDGFB驱动肿瘤生长。
- 早期清除TAM加速RAS驱动肿瘤生长,对其他PDGFB和RAS驱动模型无影响。
- PLX3397抵抗的RAS驱动肿瘤对PI3K信号抑制无反应。
- PDGFB驱动胶质瘤诱导促瘤小胶质细胞扩增和活化。
- RAS驱动间质样胶质瘤TAM富集促炎和血管生成信号。
临床怎么用
- TAM靶向治疗需根据胶质瘤分子亚型分层。
- 间质样胶质瘤可考虑CSF1R抑制联合抗血管生成。
- 微环境特征分析有助于优化TAM靶向患者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor-associated macrophages/microglia (TAMs) are prominent microenvironment components in human glioblastoma (GBM) that are potential targets for anti-tumor therapy. However, TAM depletion by CSF1R inhibition showed mixed results in clinical trials. We hypothesized that GBM subtype-specific tumor microenvironment (TME) conveys distinct sensitivities to TAM targeting. METHODS: We generated syngeneic PDGFB- and RAS-driven GBM models that resemble proneural-like and mesenchymal-like gliomas, and determined the effect of TAM targeting by CSF1R inhibitor PLX3397 on glioma growth. We also investigated the co-targeting of TAMs and angiogenesis on PLX3397-resistant RAS-driven GBM. Using single-cell transcriptomic profiling, we further explored differences in TME cellular compositions and functions in PDGFB- and RAS-driven gliomas. RESULTS: We found that growth of PDGFB-driven tumors was markedly inhibited by PLX3397. In contrast, depletion of TAMs at the early phase accelerated RAS-driven tumor growth and had no effects on other proneural and mesenchymal GBM models. In addition, PLX3397-resistant RAS-driven tumors did not respond to PI3K signaling inhibition. Single-cell transcriptomic profiling revealed that PDGFB-driven gliomas induced expansion and activation of pro-tumor microglia, whereas TAMs in mesenchymal RAS-driven GBM were enriched in pro-inflammatory and angiogenic signaling. Co-targeting of TAMs and angiogenesis decreased cell proliferation and changed the morphology of RAS-driven gliomas. CONCLUSIONS: Our work identifies functionally distinct TAM subpopulations in the growth of different glioma subtypes. Notably, we uncover a potential responsiveness of resistant mesenchymal-like gliomas to combined anti-angiogenic therapy and CSF1R inhibition. These data highlight the importance of characterization of the microenvironment landscape in order to optimally stratify patients for TAM-targeted therapy.
引用
- Rao R, Han R, Ogurek S, et al. Glioblastoma genetic drivers dictate the function of tumor-associated macrophages/microglia and responses to CSF1R inhibition. Neuro Oncol. 2022. PMID: 34562087. doi:10.1093/neuonc/noab228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。